The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > REGULATORY
REGULATORY
- PM Advisors Make Irregular Call for Properly Rewarding Innovation to Boost Japan’s Drug Discovery Capabilities
May 29, 2023
- Gene Therapy Luxturna Now in Line for Approval in June
May 29, 2023
- Relief Claims OK’ed for 14 More Deaths Possibly Tied to COVID Jabs
May 29, 2023
- Japan Approves Label Expansions for Ultomiris, Skyrizi, Vanflyta
May 26, 2023
- Expert Panel Meeting Canceled Due to Lack of Coordination: MHLW Official
May 26, 2023
- Expedite Introduction of High-Priority Vaccines into National Schedule: Trade Groups
May 25, 2023
- Orphan Tag Granted to Opdivo, Leniolisib, and 6 More APIs
May 24, 2023
- LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
- Ophthalmic Mitomycin, OD Tablets for Takecab and Tarlige to Get Listing on May 24
May 23, 2023
- MHLW Cancels Expert Panel Meeting on May 23, Report Delayed
May 23, 2023
- Ferring’s Oral Budesonide for UC Treatment Up for Advisor Review on June 2
May 22, 2023
- PMDA Reviewing Safety Risks for Opdivo, Yervoy
May 22, 2023
- Novo Mum over Pass on Wegovy Listing in May
May 19, 2023
- Japan Eyes Pilot Program for OTC-Switching of Emergency Contraceptives, Public Commenters Overwhelmingly Positive
May 18, 2023
- LDP Committee Calls for Setting Up Asian Hub of PMDA
May 18, 2023
- Industry Associations Stress Special Cost Structure of SaMD in Chuikyo Hearing
May 18, 2023
- Market Expansion Re-Pricing to Hit Tarlige, Entresto, Verzenio; Spillover to 2 Other Meds
May 18, 2023
- Deregulation Panel Eyes Use of Medical Data “Without Patient Consent”
May 17, 2023
- LDP Project Team to Finalize Pharma Policy Proposal for Honebuto by May-End, Submit It to Prime Minister
May 17, 2023
- Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
May 17, 2023
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…